Eucrisa generics — when can they launch?
Eucrisa (Crisaborole) · Anacor Pharms Inc · 8 active US patents · 0 expired
Where Eucrisa sits in the generic timeline
Imminent generic cliff: earliest active US patent for Eucrisa expires in 2027 (~1 year from today). ANDA filers are likely already preparing Paragraph IV certifications. Expect first-filer 180-day exclusivity competition imminently.
Under US Hatch-Waxman, a generic enters via an ANDA (Abbreviated New Drug Application) and may file with one of four Paragraph IV certifications attacking the brand's listed patents. If the brand sues within 45 days, a 30-month FDA approval stay is triggered. First Para IV filer typically gets 180-day market exclusivity.
Patent estate by type — active patents
Method-of-use patents only carve out specific indications; generics can launch with a "skinny label" omitting those uses. Composition-of-matter patents block the molecule itself.
- Other — 4 patents
- Method of Use — 3 patents
- Composition of Matter — 1 patent
FDA U-codes carved out by Eucrisa patents
Method-of-use patents are listed against specific FDA Patent Use Codes ("U-codes") representing carved-out indications. Generics can launch with a label that omits these uses.
| U-code | Description |
|---|---|
U-1932 | (no description) |
Sample patent estate
Showing 6 of 8 active US patents. View full estate on the Eucrisa drug page →
-
This patent discloses methods of treating anti-inflammatory conditions using boron-containing small molecules.USPTO title: Boron-containing small molecules as anti-inflammatory agents
-
This patent discloses methods of treating anti-inflammatory conditions using boron-containing small molecules.USPTO title: Boron-containing small molecules as anti-inflammatory agents
-
This patent protects methods of treating anti-inflammatory conditions using boron-containing small molecules.USPTO title: Boron-containing small molecules as anti-inflammatory agents
-
This patent discloses methods of treating anti-inflammatory conditions using boron-containing small molecules.USPTO title: Boron-containing small molecules as anti-inflammatory agents
-
This patent protects boron-containing compounds useful for treating fungal infections, particularly onychomycosis and cutaneous fungal infections, through topical application.USPTO title: Boron-containing small molecules
-
This patent protects boron-containing compounds that can be used to treat fungal infections, such as onychomycosis and cutaneous fungal infections.USPTO title: Boron-containing small molecules
Sources
- FDA Orange Book — patents listed against Eucrisa (NDA filed 2016)
- Eucrisa drug profile — full patent estate, indications, clinical trials, pricing
- Anacor Pharms Inc patent portfolio
- Patent cliff 2027 — every drug losing US exclusivity that year
Patent term extensions (PTR, pediatric exclusivity), Hatch-Waxman 30-month stays, and FDA regulatory exclusivity (NCE/ODE/PED) may shift the effective generic entry date. Not legal advice.
Get generic entry alerts
Free Pharma CI alerts on Eucrisa — get notified the moment an ANDA Paragraph IV certification is filed, a 30-month stay is triggered, or a generic launches. First 2 drugs free.
Subscribe free →